Skip to main content
. 2021 Oct 19;3(4):467–487. doi: 10.1016/j.jaccao.2021.09.003

Table 4.

Prognostic Impact of AL Amyloidosis Staging Systems

Mayo Clinic (2004) Integrating European Collaborative Study 3B Staging
Mayo Clinic (2012)
Risk Factors Risk Factors Present (n) Stage Patients (%) Median OS (months) Risk Factors Risk Factors Present (n) Stage Patients (%) Median OS (Months)
cTnT >0.035 ng/mL
NT-proBNP >332 pg/mL
0 1 33 86 cTnT >0.025 ng/mL
NT-proBNP >1,800 pg/mL dFLC >180 mg/L
0 1 25 94.1
1 2 30 43 1 2 27 40.4
2 3A 18 17 2 3 25 14
NT-proBNP ≥8,500 pg/mL 3B 19 4.6 3 4 23 5.8

The table compares the Mayo 2004 integrating the European Collaborative Study vs Mayo 2012 staging systems for AL amyloidosis (15, 16, 17).

cTnT = cardiac troponin T; NT-proBNP = N-terminal pro–B-type natriuretic peptide; OS = overall survival.